Table 1 Baseline characteristics of patients and controls in the peripheral blood study.

From: Involvement of Monocyte Subsets in the Immunopathology of Giant Cell Arteritis

 

nGCA (N = 22)

nPMR (N = 20)

HC (N = 24)

Age (yr); Median (range)

71 (52–81)

75 (54–84)

72 (53–83)

Females (%)

73

70

75

GCA diagnosis: PET-CT/TAB/PET-CT + TAB

11/5/6

NA

NA

PMR diagnosis: PET-CT/Chuang/PET-CT + Chuang

1/0/4

1/6/13

NA

Leukocytes (109/L); Median (Range)

9.2 (5.0–18.4) p < 0.0001

8.7 (4.5–14.4) p = 0.0011

6.0 (4.2–9.6)

Hb (mmol/l); Median (Range)

7.0 (5.5–8.5) p < 0.0001

7,5 (5.6–9.3) p < 0.0001

8,7 (7.2–9.9)

ESR (mm/h); Median (Range)

65 (31–118) p < 0.0001

52 (30–124) p < 0.0001

12 (2–30)

CRP (mg/l); Median (Range)

47 (11–138) p < 0.0001

44 (7–186) p < 0.0001

2 (2–5)

  1. Characteristics of newly diagnosed glucocorticoid/DMARD-free GCA (nGCA) and PMR patients (nPMR) and of healthy controls (HC). Five out of 22 GCA patients also had PMR. In 14 out of 20 PMR patients LV-GCA was excluded based on PET-CT. Importantly, the diagnosis of PMR did not change into GCA during a minimal follow-up of 6 months. The Kruskal-Wallis test was performed to compare data among the three study groups. The Mann-Whitney U test was used to compare each patient group with HC. P-values of less than 0.05 (2-tailed) were considered statistically significant. Yr = years. PET-CT = positron emission tomography-computed tomography. TAB = temporal artery biopsy. Hb = haemoglobin, ESR = erythrocyte sedimentation rate. CRP = C-reactive protein. NA = not applicable.
Back to article page